Bayer Co.Lab

🚀 Innovation accelerates when diverse ecosystems learn together.   We successfully hosted a Bayer Co.Lab Connect #Seoul Local Workshop in Seoul, bringing together seven innovative Korean startups, Korea Drug Development Fund (KDDF), venture capital partners, and Bayer | Pharmaceuticals colleagues from Korea, Japan, and China last week.   At the heart of the workshop were two key principles: "Co-learning" and "Co-creation". Its success was driven by the active engagement of every participant—openly sharing experiences, challenging perspectives, and exploring new possibilities together. For startups, discussions with experienced industry experts are often invaluable in identifying alternative development paths, refining strategies, and uncovering new partnership opportunities. It was encouraging to see so many meaningful conversations take place throughout the workshop.   Thank you to Bayer Co.Lab Connect Seoul, Japan, and China colleagues that worked seamlessly across borders to strengthen the innovation ecosystem in Asia. Special thanks to Nobu Kazama, Kazuyuki Dan, Shirley (Di) Xu and Myungkyu Noh, whose leadership, energy, and commitment to connecting people and ideas made this truly an Asia-wide collaboration. Looking forward to building on this momentum and continuing to foster meaningful connections across the region.

Aerska is grateful to be featured in a new Nature Portfolio article exploring the rapidly evolving field of brain delivery 🧠   In the article, Elie Dolgin argues that brain delivery has reached an inflection point. Denali’s recent FDA approval of tividenofusp alfa helped validate receptor-mediated delivery as a clinically viable strategy. The next phase is about optimising these systems for different cargoes, cell types and therapeutic applications.   TfR1 is currently the most clinically mature route into the brain, but different cargoes may require different delivery strategies. For RNA medicines, success means not only crossing the blood–brain barrier, but reaching the relevant cells, entering them efficiently and engaging an intracellular target.   The opportunity ahead is to match the right delivery approach to the right therapeutic application. We’re proud to be included among the companies helping to shape that future!

From Silicon Valley to Berlin. 🌎 We’re excited to welcome Phinomics to Bayer Co.Lab Berlin. As the first US-founded company to establish its European footprint at our Berlin site, this marks a new milestone for our community, and one that reflects exactly what we set out to build.  Our Berlin site is a #launchpad into Europe: space to work, close proximity to Bayer, and a strong ecosystem, so international teams can hit the ground running from day one. Phinomics has built a proprietary multi-omics platform centered on expanding the observable universe of measurable biology, starting with the #Circulome: extrachromosomal circular DNA, an emerging driver of cancer biology. By combining previously hidden layers of biology with AI, the team aims to uncover novel disease mechanisms and therapeutic targets. From Bayer Co.Lab Berlin, Phinomics will work with partners to move these discoveries towards clinical validation - with one of Europe’s most concentrated life science ecosystems on the doorstep. A warm welcome to Massa Shoura, Stephen Levene, Guido Mathews, and the entire Phinomics team. We’re glad to have you as part of the Co.Lab community and look forward to supporting your journey from Berlin. Read the press release here:  https://lnkd.in/gizxfeMd

🧬📣 The future of medicine is being written through collaboration. Are you building the next generation of RNA-based therapeutics? Come join Bayer Co.Lab Cambridge and our little center of RNA therapeutics excellence. 🔗🚀 We were thrilled to host Laura Sepp-Lorenzino, Ph.D. (Board Member at AskBio Inc.), for an impactful afternoon of strategic discussions with our pioneer tenant companies leading the charge in RNA-based therapeutics. Representing groundbreaking innovation across renal, cardiovascular, oncology, and neurological diseases, these exceptional startups showcased the frontier of RNA as a transformative modality. They shared bold perspectives on navigating the journey from discovery to development, emphasizing a shared core truth: groundbreaking science only reaches its full potential when aligned with patient needs. Through our unique co-location model, Bayer Co.Lab Cambridge provides emerging biotech innovators with direct access to Bayer Discovery R&D, our Business Development & Licensing (BD&L) teams, and world-class laboratory infrastructure. By bridging experienced industry leadership with next-generation innovators, we are actively accelerating the next wave of therapeutics in oncology, immunology, and beyond. A sincere thank you to Laura and all the participating founders and scientific leaders for sharing their vision and expertise. Let’s keep on shaping the future of healthcare. Alberto Nobili, Tatiana Novobrantseva, Matthew Stanton, Poorya Hosseini, Chris Bahl, Stuart Milstein, Leo Qian, Sriram Sathyanarayanan, and Paul Vogel. #BayerCoLab #RNATherapeutics #BiotechInnovation #TranslationalScience #PharmaCoLab #LifeSciences

From China to Germany, #innovation knows no borders! Our Global Head of Bayer Co.Lab, Friedemann Janus, PhD discusses why China is a key part of our strategy from our Shanghai life science incubator. [nur auf Deutsch]   https://lnkd.in/esSDjTRM Shirley (Di) Xu Kedi Zhou Tagesschau DE

Congratulations to OTR Therapeutics, a Shanghai tenant, on the 2nd partnership deal within 1 year 🎊 🎊

📢 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗟𝗜𝗡𝗞-𝗨𝗣: 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗫 𝗘𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿 𝗶𝘀 𝗯𝗮𝗰𝗸 𝗳𝗼𝗿 𝗥𝗼𝘂𝗻𝗱 𝟮! Healthcare Businesswomen’s Association and Bayer Co.Lab are excited to announce another instalment of Life Science LINK-UP. A curated and intimate event format to build bridges between the startup world and the industry world. We believe that innovation in life sciences thrives when bold ideas meet industry might. Berlin is home to incredible #startups and global #industry leaders… yet these worlds rarely collide. Life Science LINK-UP tackles this fragmentation problem head on. 📅 On October 8th in Berlin, the ecosystem will come together again. ✨ Intimate. ✨ Informal. ✨ Curated. ✨ Fun. This time, expect both startup and industry pitches. Sign-up via the short pre-registration form now, select what topics you want to talk about, and express your interest to be in the room where the conversations are happening. 🔗 https://luma.com/gslu1e05 Sejal Patel-Tolksdorf | Ruth R. Shah | Tatjana Gust | Dr. Baltrukovich Natalya, MBA, PhD | Kiliana Suzart-Woischnik | Maika Rothkegel, PhD | Kathrin Schoenborn #BayerCoLab #HBA #startup #entrepreneur #pharmaceuticals #lifesciences #biotech #medtech #digitalhealth #medicaldevices #Berlin #innovation #collaboration

📣 Deadline Extended to June 22, 2026 📣 Bayer Co.Lab is extending the application deadline for our Co.Lab Connect program. If you’re an early-stage life science startup in Switzerland or Korea translating breakthrough science into real-world impact, we welcome you to join us. Winners gain access to: 👉 Global Bayer Co.Lab sites and trusted regional partners, 👉 Direct engagement with Bayer R&D and BD&L teams, 👉 Connections to investors and ecosystem collaborators, and 👉 Flexible Co.Lab membership, including global hot desk access. If this sounds like you, we invite you to be part of the next wave of entrepreneurs shaping a dynamic, globally connected innovation community. 🎉 Excited to learn more? Apply at Bayer Co.Lab. #BayerCoLabConnect #LifeScienceStartupEcosystem #SwitzerlandKorea #GlobalInnovation 

A pleasure to welcome EU Health Commissioner Olivér Várhelyi to Bayer Co.Lab Berlin today, alongside Stefan Oelrich and other members of #TeamBayer His visit comes at a pivotal moment for European life sciences. With the upcoming EU Biotech Act, Europe is taking clear steps to strengthen its competitiveness, accelerate innovation, and enable breakthrough therapies to reach patients faster. At Bayer Co.Lab, we see every day what this ambition looks like in practice: early-stage ventures translating world-class science into scalable solutions - right here in Europe. Today’s discussions reinforced a shared priority to bridge the gap between scientific excellence and commercial scale by creating an environment where biotech companies can start, grow, and stay in Europe. We are proud to contribute to this ecosystem by: - Supporting cutting-edge startups with critical infrastructure - Connecting founders with Bayer expertise across the value chain - Embedding them in one of Europe’s most dynamic biopharma clusters, while also connecting them on the global stage Thank you, Commissioner Várhelyi, for the open exchange and your commitment to advancing Europe’s biotech future. #BiotechAct #BiotechEU #Innovation #Startups #LifeSciences #Biotech #Berlin #Ecosystem #BayerCoLab MyoPax, Captain T Cell, NeutroGen Therapeutics, EpiBlok Therapeutics GmbH, Leaps by Bayer, Ruth R. Shah, André Guillaume, Christoph Rehberger, Melissa L., Zsófia Szakony, Edouard Ohleyer, Heidi Sylvester Photo credit: European Commission / Jadranko Marjanovic

✨ Backing Visionary Entrepreneurs Yesterday's Multi-Corporate Day at the EIC Summit in Brussels was a masterclass on #startup - #corporate matching. The program is designed to spark collaborations that bring promising life science solutions closer to patients. Tailored sourcing of some of Europe's most ambitious startups combined with individual coaching and a format on the day that encourages as much conversastion as possible worked wonders. Representatives from #TeamBayer R&D and Bayer Co.Lab Berlin joined the event and met with 16 startups from across 9 different European countries. Because #innovation doesn't happen in silo's and #collaboration is critical in the business of developing medicines. Congratulations to all the startups for the fantastic prep and pitches 🙌 Aindo | BestHealth4U | Biomodics ApS | BiopSense Oy | ELEM Biotech | EVERSENS SL | iktos | InnoCon Medical | Integra Therapeutics | Lincbiotech | Neovivum | Qubit Pharmaceuticals | Scienta | Sequentia Biotech | Preemie by Tellspec | Trince Stefan Gradl, Larissa Urbanus, Philipp Cromm, Ruth R. Shah, Laura Luh, Anastasia Hager #EUeic #Europe #DrugHunters #HealthForAll